Reports

Drug name	NICE TAs	Comments
Atezolizumab (Tecentriq®)	TA492 - Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA333 - Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma TA705 - Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer	Hospital use only
Atogepant (Aquipta®)	NICE TA 973 Atogepant for preventing migrane	Use in accordance with NICE
Avacopan (Tavneos®)	TA825: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis
Avalglucosidase	TA821: Avalglucosidase alfa for treating Pompe disease
Avatrombopag	TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avatrombopag (Doptelet®)	TA853 - Avatrombopag for treating primary chronic immune thrombocytopenia TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avelumab (Bavencio®)	TA517 - Avelumab for treating metastatic Merkel cell carcinoma TA644 - Avelumab with axitinib for untreated advanced renal cell carcinoma
Axicabtagene ciloleucel (Yescarta®)	TA872 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
Axitinib	TA218 - Myelodysplastic syndromes - azacitidine	National CDF list
Azacitidine (Vidaza®)	TA827: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy	For hospital use only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports